Globus Medical, Inc. (NYSE:GMED – Get Free Report)’s stock price reached a new 52-week low during trading on Monday. The stock traded as low as $70.14 and last traded at $70.3250, with a volume of 403,238 shares traded. The stock had previously closed at $72.14.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on GMED. Canaccord Genuity Group cut their target price on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Wall Street Zen cut shares of Globus Medical from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Needham & Company LLC decreased their price target on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, November 6th. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, November 9th. Finally, Wells Fargo & Company raised their price objective on shares of Globus Medical from $99.00 to $100.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $96.08.
Read Our Latest Research Report on GMED
Globus Medical Stock Performance
The stock’s 50-day moving average price is $76.56 and its two-hundred day moving average price is $82.71. The stock has a market capitalization of $9.34 billion, a PE ratio of 17.29, a P/E/G ratio of 1.12 and a beta of 0.98.
Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The company had revenue of $763.72 million during the quarter, compared to analysts’ expectations of $792.39 million. During the same period last year, the company posted $1.18 EPS. Globus Medical’s revenue was down .7% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, analysts predict that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.
Insider Transactions at Globus Medical
In related news, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the sale, the director directly owned 25,000 shares of the company’s stock, valued at approximately $2,176,000. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ann D. Rhoads sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the sale, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. This trade represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 101,666 shares of company stock valued at $7,970,017 in the last quarter. 18.38% of the stock is owned by insiders.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Sanctuary Advisors LLC lifted its stake in Globus Medical by 2.3% in the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock worth $570,000 after purchasing an additional 151 shares in the last quarter. Summitry LLC boosted its holdings in shares of Globus Medical by 2.6% during the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after purchasing an additional 211 shares during the last quarter. Central Pacific Bank Trust Division boosted its holdings in shares of Globus Medical by 7.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 3,057 shares of the medical device company’s stock worth $229,000 after purchasing an additional 220 shares during the last quarter. Arizona State Retirement System grew its position in shares of Globus Medical by 0.8% in the second quarter. Arizona State Retirement System now owns 31,077 shares of the medical device company’s stock valued at $2,455,000 after purchasing an additional 252 shares in the last quarter. Finally, Angeles Wealth Management LLC grew its position in shares of Globus Medical by 5.0% in the second quarter. Angeles Wealth Management LLC now owns 5,894 shares of the medical device company’s stock valued at $466,000 after purchasing an additional 280 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.
Globus Medical Company Profile
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
Featured Articles
- Five stocks we like better than Globus Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
